• Home
  • About Us
  • Information updates
  • PBS listings of Dupixent (dupilumab) for uncontrolled severe asthma (1st April 2021) and severe atopic dermatitis (1st March 2021)

Information updates

PBS listings of Dupixent (dupilumab) for uncontrolled severe asthma (1st April 2021) and severe atopic dermatitis (1st March 2021)

Dupixent (dupilumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of patients aged 12 years and older with:

  • Uncontrolled severe asthma from 1st April 2021; and
  • Severe atopic dermatitis who have failed to respond to optimally prescribed topical treatments from 1st March 2021.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. IL-4 and IL-13 are key and central drivers of type 2 inflammation that plays a central role in allergic and eosinophilic asthma, as well as atopic dermatitis. Dupixent is not an immunosuppressant.

Dupixent is jointly developed by Sanofi and Regeneron under a global collaboration agreement.

Full Product Information is available from Sanofi-Aventis Australia Pty Ltd at www.guildlink.com.au/gc/ws/sw/pi.cfm?product=swpdupix or by contacting 1800 818 806.

Consumer Medicine Information (CMI) is available at www.guildlink.com.au/gc/ws/sw/cmi.cfm?product=swcdupix

Further information is available here:

pdfConsumer Media Release Dupixent Asthma PBS Listing152.05 KB

pdfMedical Media Release Dupixent Asthma PBS Listing149.21 KB

pdfDupixent® PBS listed for severe atopic dermatitis145.4 KB


Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.